Pharmacogenetic Allele Nomenclature: International Workgroup Recommendations for Test Result Reporting

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2015 Oct 20

PMID 26479518

Citations 67

Authors

L V Kalman

Jag Agundez

M Lindqvist Appell

J L Black

G C Bell

S Boukouvala

C Bruckner

E Bruford

K Caudle

S A Coulthard

A K Daly

Al Del Tredici

J T den Dunnen

K Drozda

R E Everts

D Flockhart

R R Freimuth

A Gaedigk

H Hachad

T Hartshorne

M Ingelman-Sundberg

T E Klein

V M Lauschke

D R Maglott

H L McLeod

G A McMillin

U A Meyer

D J Muller

D A Nickerson

W S Oetting

M Pacanowski

V M Pratt

M V Relling

A Roberts

W S Rubinstein

K Sangkuhl

M Schwab

S A Scott

S C Sim

R K Thirumaran

L H Toji

R F Tyndale

Rhn van Schaik

M Whirl-Carrillo

Ktj Yeo

U M Zanger

Affiliations

Soon will be listed here.

Abstract

This article provides nomenclature recommendations developed by an international workgroup to increase transparency and standardization of pharmacogenetic (PGx) result reporting. Presently, sequence variants identified by PGx tests are described using different nomenclature systems. In addition, PGx analysis may detect different sets of variants for each gene, which can affect interpretation of results. This practice has caused confusion and may thereby impede the adoption of clinical PGx testing. Standardization is critical to move PGx forward.

Citing Articles

Genetic Variants and Major Depressive Disorder: A Systematic Review.

Bonasser L, de Souza Silva C, Fratelli C, Gontijo B, Seixas J, de Sa Barreto L Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598373 PMC: 11597809. DOI: 10.3390/ph17111461.

Genetic ancestry in population pharmacogenomics unravels distinct geographical patterns related to drug toxicity.

Karamperis K, Katz S, Melograna F, Ganau F, Van Steen K, Patrinos G iScience. 2024; 27(10):110916.

PMID: 39391720 PMC: 11465127. DOI: 10.1016/j.isci.2024.110916.

Patterns of pharmacogenetic variation in nine biogeographic groups.

Hernandez S, Hindorff L, Morales J, Ramos E, Manolio T Clin Transl Sci. 2024; 17(9):e70017.

PMID: 39206687 PMC: 11358764. DOI: 10.1111/cts.70017.

Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis.

Li D, Pain O, Fabbri C, Wong W, Lo C, Ripke S Transl Psychiatry. 2024; 14(1):296.

PMID: 39025838 PMC: 11258238. DOI: 10.1038/s41398-024-02981-1.

A comprehensive Thai pharmacogenomics database (TPGxD-1): Phenotype prediction and variants identification in 942 whole-genome sequencing data.

John S, Klumsathian S, Own-Eium P, Eu-Ahsunthornwattana J, Sura T, Dejsuphong D Clin Transl Sci. 2024; 17(6):e13830.

PMID: 38853370 PMC: 11163017. DOI: 10.1111/cts.13830.

References

Malentacchi F, Mancini I, Brandslund I, Vermeersch P, Schwab M, Marc J . Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe. Clin Chem Lab Med. 2015; 53(7):981-8. DOI: 10.1515/cclm-2015-0171. View

Swen J, Huizinga T, Gelderblom H, de Vries E, Assendelft W, Kirchheiner J . Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med. 2007; 4(8):e209. PMC: 1945038. DOI: 10.1371/journal.pmed.0040209. View

Huang S, Temple R . Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther. 2008; 84(3):287-94. DOI: 10.1038/clpt.2008.144. View

Robert J, Le Morvan V, Giovannetti E, Peters G . On the use of pharmacogenetics in cancer treatment and clinical trials. Eur J Cancer. 2014; 50(15):2532-43. DOI: 10.1016/j.ejca.2014.07.013. View

Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E . VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost. 2005; 94(4):773-9. DOI: 10.1160/TH05-04-0290. View

Ma J, Lee K, Kuo G . Clinical application of pharmacogenomics. J Pharm Pract. 2012; 25(4):417-27. DOI: 10.1177/0897190012448309. View

Gordon A, Tabor H, Johnson A, Snively B, Assimes T, Auer P . Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. Hum Mol Genet. 2013; 23(8):1957-63. PMC: 3959810. DOI: 10.1093/hmg/ddt588. View

Hess G, Fonseca E, Scott R, Fagerness J . Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders. Genet Res (Camb). 2015; 97:e13. PMC: 6863636. DOI: 10.1017/S0016672315000099. View

Pratt V, Everts R, Aggarwal P, Beyer B, Broeckel U, Epstein-Baak R . Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project. J Mol Diagn. 2015; 18(1):109-23. PMC: 4695224. DOI: 10.1016/j.jmoldx.2015.08.005. View

10.

Abul-Husn N, Obeng A, Sanderson S, Gottesman O, Scott S . Implementation and utilization of genetic testing in personalized medicine. Pharmgenomics Pers Med. 2014; 7:227-40. PMC: 4157398. DOI: 10.2147/PGPM.S48887. View

11.

Stanek E, Sanders C, Taber K, Khalid M, Patel A, Verbrugge R . Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012; 91(3):450-8. DOI: 10.1038/clpt.2011.306. View

12.

Lee K, Ma J, Kuo G . Pharmacogenomics: bridging the gap between science and practice. J Am Pharm Assoc (2003). 2010; 50(1):e1-14. DOI: 10.1331/JAPhA.2010.09124. View

13.

Urban T . Race, ethnicity, ancestry, and pharmacogenetics. Mt Sinai J Med. 2010; 77(2):133-9. DOI: 10.1002/msj.20168. View

14.

Watson M, Cutting G, Desnick R, Driscoll D, Klinger K, Mennuti M . Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med. 2004; 6(5):387-91. PMC: 3110945. DOI: 10.1097/01.gim.0000139506.11694.7c. View

15.

Kroetz D, Pauli-Magnus C, Hodges L, Huang C, Kawamoto M, Johns S . Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003; 13(8):481-94. DOI: 10.1097/00008571-200308000-00006. View

16.

Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena A . Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics J. 2015; 15(3):201-10. DOI: 10.1038/tpj.2014.86. View

17.

Caudle K, Thorn C, Klein T, Swen J, McLeod H, Diasio R . Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013; 94(6):640-5. PMC: 3831181. DOI: 10.1038/clpt.2013.172. View

18.

Robarge J, Li L, Desta Z, Nguyen A, Flockhart D . The star-allele nomenclature: retooling for translational genomics. Clin Pharmacol Ther. 2007; 82(3):244-8. DOI: 10.1038/sj.clpt.6100284. View

19.

Mallal S, Phillips E, Carosi G, Molina J, Workman C, Tomazic J . HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008; 358(6):568-79. DOI: 10.1056/NEJMoa0706135. View

20.

Pirmohamed M . Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annu Rev Genomics Hum Genet. 2014; 15:349-70. DOI: 10.1146/annurev-genom-090413-025419. View